Skip to content

Author

O. Galal

We have 2 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.

It is demonstrated that simultaneous targeting of iron overload and antioxidant signaling confers enhanced cardioprotection against Dox-induced injury and the Lira-DFO combination may represent a promising adjunct strategy to mitigate anthracycline-associated cardiotoxicity.

Nada Monir, O. Galal, A. Awad et al. · 0 citations
Open access Aug 2026

Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling

Buspirone pretreatment mitigated CPA-induced renal dysfunction, accompanied by increased miR-205 expression, reduced EGLN2 expression, enhanced Nrf2-associated antioxidant defenses, and attenuation of ER stress, inflammation, and apoptosis, thereby preserving renal function and tissue integrity.

Ahmed M. El-Dessouki, A. Alrashidi, Mohammad I Jumaa et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.